Provention bio announces biologics license application (bla) resubmission for teplizumab to address complete response letter (crl)

Red bank, n.j., feb. 22, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb) (the "company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced it has resubmitted the biologics license application (bla) for teplizumab for the delay of clinical type 1 diabetes (t1d) in at-risk individuals.
PRVB Ratings Summary
PRVB Quant Ranking